Nitrome Biosciences

View All

recent-pharma-news
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Find More